Association of HLA-A∗11:01, HLA-B∗39:01, and HLA-B∗56:03 with salazosulfapyridine-induced cutaneous adverse drug reactions

Affiliations

• ¹ Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan.
• ² Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan.
• ³ Department of Integrative Medical Science for Allergic Disease, Fujita Health University School of Medicine, Nagoya, Japan.
• ⁴ Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
• ⁵ Department of Dermatology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
• ⁶ Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
• ⁷ Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan.
• ⁸ Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
• ⁹ Department of Dermatology, Faculty of Medicine, Shimane University, Shimane, Japan.
• ¹⁰ Department of Dermatology, School of Medicine, Nara Medical University, Kashihara, Japan.
• ¹¹ Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. Electronic address: mushiroda@riken.jp.